New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease

Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides...

Full description

Saved in:

Bibliographic Details
Published in:	Terapevtic̆eskii arhiv Vol. 91; no. 3; pp. 76 - 85
Main Authors:	Avdeev, S N, Trushenko, N V
Format:	Journal Article
Language:	English Russian
Published:	Russia (Federation) "Consilium Medicum" Publishing house 30-03-2019
Subjects:	aclidinium/formoterol combination chronic obstructive pulmonary disease dual bronchodilation therapy aclidinium/formoterol combination dual bronchodilation therapy chronic obstructive pulmonary disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides different clinical effects and new opportunities for personalized treatment of COPD. Aclidinium/formoterol fixed combination differs from other dual bronchodilators by twice-daily dosing regimen, good safety profile and a specific delivery system. Recent information on clinical efficacy and safety of aclidinium/formoterol combination in COPD patients is given in this article.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0040-3660 2309-5342
DOI:	10.26442/00403660.2019.03.000136